|
Sep 26
|
Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
|
|
Sep 26
|
Sector Update: Health Care Stocks Mixed Late Afternoon
|
|
Sep 26
|
Top Midday Gainers
|
|
Sep 26
|
Why Is Pasithea Therapeutics Stock Surging On Thursday?
|
|
Sep 26
|
Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
|
|
Jun 13
|
Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial
|
|
May 28
|
Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting
|
|
Jan 2
|
Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients
|
|
Dec 28
|
Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023
|
|
Dec 19
|
Pasithea Therapeutics Announces Results from 2023 Annual Meeting
|
|
Nov 29
|
Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders
|
|
Nov 29
|
Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development
|
|
Nov 9
|
Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS
|
|
Jun 30
|
Pasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of Directors
|
|
Jun 29
|
Lucy Scientific Discovery Reiterates Its Proposal to Acquire Pasithea Therapeutics Corp.
|
|
Jun 29
|
Pasithea Therapeutics Announces Completion of GMP Manufacturing for PAS-004
|